Prolight secures patent in Japan for Psyros™ technology

Prolight Diagnostics announces today that the company’s patent for the Psyros™ technology for single molecule counting has officially been granted in Japan by the Japan Patent Office (JPO). The patent is valid until 2040.

“This milestone represents another major advancement for the Prolight intellectual property portfolio and enhances the attractiveness of our technology to potential international commercial partners,” said Ulf Bladin, CEO of Prolight.

For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Prolight secures patent in Japan for Psyros™ technology

Prolight secures patent in Japan for Psyros™ technology
Back

Subscribe